Patent · US Active

Interleukin 15 as selectable marker for gene transfer in lymphocytes

US9487800B2 · kind B2 · utility

34Cited by

0References

6Claims

0Family size

Assignee

CHEMOTHERAPEUTISCHES FORSCHUNGSINSTITUT GEORG-SPEYER-HAUS · DE

Inventors

Kurt Schonfeld · Langen, DE
Christiane Knopp · Langen, DE
Winfried Wels · Emmendingen, DE

Key dates

Filing date	Sep 6, 2011
Grant date	Nov 8, 2016
Priority date	—
Expiry date	Aug 24, 2032

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2740/16043
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to the use of interleukin-15 (IL-15) as selectable marker for gene transfer, preferably of at least one gene of therapeutic interest, into a mammalian cell or cell line, in particular a human cell or cell line. The present invention furthermore relates to transgenic mammalian cells or cell lines expressing IL-15 as selectable marker and co-expressing at least one protein of interest encoded by at least one gene of interest, which is preferably a protein of therapeutic interest. The present invention is in particular suitable for chimeric antigen receptors (CARs) as the gene or protein of interest and their expression in lymphocytes. The transgenic mammalian cells and cell lines are furthermore suitable for use as a medicament, in particular in the treatment of cancer and in immunotherapy, such as adoptive, target-cell specific immunotherapy.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.